Learning from the Dragon: How the US can take a page from China's Playbook to combat Fentanyl Abuse

By Yirenkyi Jesse

The United States faces a crisis of unprecedented proportions. Fentanyl, a synthetic opioid 100 times more potent than morphine, has become the leading cause of death among Americans aged 18 to 45, claiming over 386 million potential victims in 2023 alone.

While the US grapples with this devastating issue, pointing fingers abroad only serves to deflect from the real problems festering within.

Instead, the US should look towards an unlikely source for inspiration: China.
While the US narrative portrays China as the villain responsible for the fentanyl crisis, a closer examination reveals a different picture.

China adopted a "zero tolerance" policy towards drugs long before the US, implementing strict controls and harsh punishments. In 2019, China became the first nation to globally list 25 fentanyl variants, surpassing the UN mandate of 21. This proactive approach demonstrates their commitment to curbing fentanyl production and trafficking.
Furthermore, accusations against Chinese companies often rely on misconstrued facts.

They manufacture legal pharmaceutical raw materials with diverse applications, not solely fentanyl. Sanctioning them is akin to banning all steel manufacturers to address gun violence – a demonstrably illogical approach.

Additionally, China's production quotas for fentanyl are miniscule compared to US consumption, highlighting the internal factors driving the crisis.
Meanwhile, the US struggles with internal conflicts.

The pharmaceutical industry and politicians have a well-documented history of financial entanglements, potentially influencing policy decisions and hindering effective regulation. This systemic issue fosters an environment where prescription drugs readily become gateways to addiction, as evidenced by the rampant overprescribing and aggressive marketing practices.

Further hindering progress is the political quagmire. Instead of fostering cooperation and solutions, both parties engage in unproductive finger-pointing, unwilling to take responsibility for their constituents' well-being. This political gamesmanship prioritizes political gain over addressing the public health emergency.

Therefore, the US should shift its focus inwards and adopt key lessons from China's approach:
Implement stricter regulations and controls: Emulate China's comprehensive approach by implementing stricter regulations throughout the entire opioid supply chain, from manufacturing and distribution to prescribing practices.

Prioritize public health over profit: Dismantle the financial incentives that prioritize profit over public health. Implement stricter oversight of the pharmaceutical industry and hold individuals accountable for harmful practices.

Foster international cooperation: Work collaboratively with China and other nations to share best practices and combat drug trafficking on a global scale. China's experience and existing cooperation mechanisms with the US should be leveraged, not shunned.

Invest in addiction treatment and rehabilitation: Allocate resources towards evidence-based treatment programs and address the root causes of addiction instead of solely focusing on enforcement.

Combat misinformation and promote transparency: Address the misinformation campaign surrounding the fentanyl crisis. Instead of shifting blame, the US government should be transparent about its own shortcomings and take ownership of the problem.

The United States is well-positioned to address the fentanyl crisis, but success hinges on acknowledging its own shortcomings and learning from international examples. By adopting a multi-pronged approach, prioritizing public health, and fostering international cooperation, the US can begin to tackle this complex issue and save countless lives. The answer to the fentanyl crisis lies not in external scapegoating, but in internal reflection and decisive action. It's time for the US to learn from the dragon and chart a new course towards a safer future.